| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MMP23A |
| Uniprot No | O75900 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-390aa |
| 氨基酸序列 | MGRGARVPSEAPGAGVERRWLGAALVALCLLPALVLLARLGAPAVPAWSA AQGDVAALGLSAVPPTRVPGPLAPRRRRYTLTPARLRWDHFNLTYRILSF PRNLLSPRETRRALAAAFRMWSDVSPFSFREVAPEQPSDLRIGFYPINHT DCLVSALHHCFDGPTGELAHAFFPPHGGIHFDDSEYWVLGPTRYSWKKGV WLTDLVHVAAHEIGHALGLMHSQHGRALMHLNATLRGWKALSQDELWGLH RLYGCLDRLFVCASWARRGFCDARRRLMKRLCPSSCDFCYEFPFPTVATT PPPPRTKTRLVPEGRNVTFRCGQKILHKKGKVYWYKDQEPLEFSYPGYLA LGEAHLSIIANAVNEGTYTCVVRRQQRVLTTYSWRVRVRG |
| 预测分子量 | 43,9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MMP23A重组蛋白的3篇代表性文献示例(注：MMP23A研究相对较少，部分文献可能涉及MMP23而非MMP23A亚型)：
1. **文献名称**：*"Expression and characterization of recombinant human MMP-23A: Role in ovarian cancer progression"*
**作者**：Smith J, et al.
**摘要**：报道了人源MMP23A重组蛋白在昆虫细胞中的表达与纯化，并发现其在卵巢癌细胞中过表达可促进侵袭转移，可能通过调控细胞外基质降解发挥作用。
2. **文献名称**：*"MMP23A negatively regulates TLR signaling by modulating TRAF6 ubiquitination in macrophages"*
**作者**：Chen L, et al.
**摘要**：通过大肠杆菌系统表达MMP23A胞外结构域重组蛋白，发现其通过抑制TRAF6泛素化负调控TLR通路，提示其在炎症反应中的免疫调节功能。
3. **文献名称**：*"Structural insights into MMP23A: Crystal structure of the catalytic domain"*
**作者**：Wang Y, et al.
**摘要**：解析了MMP23A催化结构域重组蛋白的晶体结构，揭示其独特的锌离子结合模体，为设计选择性抑制剂提供结构基础。
**注意**：MMP23A相关研究较为有限，上述内容为模拟示例。建议通过PubMed等数据库以“MMP23A recombinant”或“MMP23 expression”为关键词检索最新文献。部分研究可能聚焦于MMP23(不特指A亚型)的重组表达与功能分析。
MMP23A (Matrix Metalloproteinase 23A) is a unique member of the matrix metalloproteinase (MMP) family, zinc-dependent endopeptidases traditionally known for their roles in extracellular matrix (ECM) remodeling. Unlike most MMPs, MMP23A exhibits distinct structural and functional characteristics. It is classified as a type II transmembrane protein, anchored to the plasma membrane via a C-terminal transmembrane domain, which distinguishes it from secreted MMPs. The enzyme is synthesized as an inactive zymogen containing a propeptide domain that requires proteolytic cleavage for activation. Notably, MMP23A lacks the hemopexin-like domain found in many MMPs, which is critical for substrate recognition and interactions with inhibitors.
Originally identified in ovarian carcinoma cells, MMP23A is encoded by the *MMP23* gene located on chromosome 1p36.3 in humans. Its expression is observed in reproductive tissues, the nervous system, and certain cancers, suggesting context-dependent roles in physiological and pathological processes. Functionally, MMP23A may regulate cell adhesion, inflammation, and tissue homeostasis by processing substrates such as proteoglycans, cytokines, or cell surface receptors. Emerging studies link it to cancer progression, where it may modulate tumor microenvironment signaling, though its exact mechanisms remain debated.
Recombinant MMP23A is produced using expression systems (e.g., *E. coli* or mammalian cells) for structural and functional studies. Tags like His-tags or FLAG-tags are often added to facilitate purification and detection. Research on recombinant MMP23A aims to clarify its substrate specificity, activation pathways, and potential as a therapeutic target or biomarker in diseases like cancer or inflammatory disorders. Its membrane-bound nature and atypical structure make it a compelling subject for exploring MMP functional diversity and disease intervention strategies.
×
